Haisco licenses two drug candidates to Nuvectis in potential $1.4 billion deal
Nuvectis gains global rights outside select Asian markets for oncology and complement disease therapies, with Haisco eligible for milestone payments and royalties
Nuvectis gains global rights outside select Asian markets for oncology and complement disease therapies, with Haisco eligible for milestone payments and royalties
Around 85% of ALS patients suffer from a progressive loss of bulbar functionality
Subscribe To Our Newsletter & Stay Updated